The US Food and Drug Administration has granted de novo authorization to Paige.AI.’s Paige Prostate medical software to aid pathologists in finding prostate cancer. According to the agency, clinical data shows it significantly improved the detection of cancerous cells that otherwise would have gone unnoticed.
Paige, spun off from New York’s Memorial Sloan Kettering Cancer Center, develops artificial intelligence medical software to analyze diagnostic imaging...